$8.68
0.00%
Nasdaq, Mon, Aug 11 2025
ISIN
US78667J1088
Symbol
SAGE

SAGE Therapeutics, Inc. Stock price

$8.68
-0.59 6.36% 1M
+1.49 20.72% 6M
+3.25 59.85% YTD
+0.82 10.43% 1Y
-33.30 79.32% 3Y
-42.69 83.10% 5Y
-55.20 86.41% 10Y
-21.42 71.16% 20Y
Nasdaq, Closing price Mon, Aug 11 2025
+0.00 0.00%
ISIN
US78667J1088
Symbol
SAGE
Industry

Key metrics

Basic
Market capitalization
$543.6m
Enterprise Value
$178.0m
Net debt
positive
Cash
$365.6m
Shares outstanding
62.6m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
7.7 | 6.5
EV/Sales
2.5 | 2.1
EV/FCF
negative
P/B
1.5
Financial Health
Equity Ratio
85.0%
Return on Equity
-86.2%
ROCE
-80.0%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$70.4m | $84.0m
EBITDA
$-302.1m | $-245.6m
EBIT
$-302.7m | $-246.9m
Net Income
$-301.2m | $-230.1m
Free Cash Flow
$-289.3m
Growth (TTM | estimate)
Revenue
-27.6% | 103.6%
EBITDA
37.3% | 40.0%
EBIT
37.3% | 39.9%
Net Income
32.4% | 42.6%
Free Cash Flow
22.6%
Margin (TTM | estimate)
Gross
-
EBITDA
-429.1% | -292.5%
EBIT
-430.0%
Net
-427.8% | -274.0%
Free Cash Flow
-410.9%
More
EPS
$-4.8
FCF per Share
$-4.6
Short interest
3.9%
Employees
353
Rev per Employee
$120.0k
Show more

Is SAGE Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,027 stocks worldwide.

SAGE Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

17 Analysts have issued a SAGE Therapeutics, Inc. forecast:

6x Buy
35%
11x Hold
65%

Analyst Opinions

17 Analysts have issued a SAGE Therapeutics, Inc. forecast:

Buy
35%
Hold
65%

Financial data from SAGE Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
70 70
28% 28%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 227 227
6% 6%
323%
- Research and Development Expense 138 138
54% 54%
196%
-302 -302
37% 37%
-429%
- Depreciation and Amortization 0.60 0.60
55% 55%
1%
EBIT (Operating Income) EBIT -303 -303
37% 37%
-430%
Net Profit -301 -301
32% 32%
-428%

In millions USD.

Don't miss a Thing! We will send you all news about SAGE Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

SAGE Therapeutics, Inc. Stock News

Positive
The Motley Fool
11 days ago
Sage (SAGE) Q2 Revenue Jumps 264%
Neutral
Business Wire
13 days ago
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq: SAGE), today reported business highlights and financial results for the second quarter ended June 30, 2025. “Our second quarter results reflect revenue acceleration driven by increased investment, strong execution, and growing momentum behind ZURZUVAE, underscoring our collective commitment to advancing care for women with post...
Neutral
Business Wire
29 days ago
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Sage Therapeutics, Inc. (NasdaqGM: SAGE) to Supernus Pharmaceuticals, Inc. (NasdaqGM: SUPN). Under the terms of the proposed transaction, Sage shareholders will receive $8.50 per share in cash, plus one...
More SAGE Therapeutics, Inc. News

Company Profile

SAGE Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel medicines to treat life-altering central nervous system. Its programs include brexanolone, which is an acute interventional treatment for postpartum depression; and SAGE-217, an oral therapy for treatment of various CNS disorders. The company was founded by Steven Marc Paul and Douglas Covey in April 2010 and is headquartered in Cambridge, MA.

Head office United States
CEO Barry Greene
Employees 353
Founded 2010
Website www.sagerx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today